Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 49,800 shares, a drop of 42.4% from the September 30th total of 86,400 shares. Based on an average trading volume of 70,900 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.0% of the company’s shares are short sold. Approximately 1.0% of the company’s shares are short sold. Based on an average trading volume of 70,900 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.50.

Aprea Therapeutics Stock Up 0.7%

Shares of APRE traded up $0.01 during midday trading on Monday, reaching $1.41. The company had a trading volume of 35,189 shares, compared to its average volume of 48,120. Aprea Therapeutics has a 1-year low of $1.31 and a 1-year high of $5.00. The stock has a market cap of $8.22 million, a PE ratio of -0.61 and a beta of 1.30. The firm has a 50 day simple moving average of $1.50 and a 200-day simple moving average of $1.64.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.24. The firm had revenue of $0.12 million during the quarter. Aprea Therapeutics had a negative return on equity of 78.90% and a negative net margin of 1,645.01%. As a group, sell-side analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.